| abstract |
An agent that suppresses Mcl-1 expression or Mcl-1 polypeptide activity for use in treating a disease or condition of the eye associated with pathological neovascularization, wherein the disease or condition is selected from the group consisting of Diabetic retinopathy, choroidal or retinal pathological neovascularization, senile macular degeneration, retinopathy of prematurity, ocular trauma or ischemia, surgical-induced edema or neovascularization, retinal vein occlusion, Coats disease, sickle cell retinopathy, and neovascular glaucoma. |